Task 2.1 - Development of Strategic Research Agenda, roadmap and priorities for research on low dose risk

Lead: MELODI
Partner: BfS, MTA-EK, DH-PHE, HMGU, IRSN, STUK, ENEA, UniPv, CEA; LTPs: CTU-FBME, CREAL, SU
MELODI (Multidisciplinary European Low dose Initiative)

MELODI Working Group SRA

- Michaela Kreuzer (Chair), BfS, Germany
- Imre Balashazy, MTA-EK, Hungary
- Simon Bouffler, PHE, UK
- Elisabeth Cardis, CREAL, Spain
- Peter Jacob, HMGU, Germany
- Mats Harms-Ringdahl, SU, Sweden
- Jean-Rene Jourdain, IRSN, France
- Katja Kojo, STUK, Finland
- Simona Pazzaglia, ENEA, Italy
- Friedo Zölzer, Czech Republic

- Kevin Prise, UK
- Dietrich Averbeck, IRSN, France

Strategic Research Agenda of the Multidisciplinary European Low Dose Initiative (MELODI)


A. Ottolenghi, L. Sabatier

Status: 13 June 2014
MELODI WG SRA
- Activities -

• Annual update of the SRA

• Preparation of a short MELODI statement, presenting the top priorities (only in years when a call will be launched)

• Open consultation process via website and the MELODI workshop

• Updated SRA and statement are sent by the WG SRA to the MELODI Board of Directors for comments and approval

• Final review by the independent Scientific Committee of MELODI
Process of development of SRA and statement

Open consultation (Website, workshops)

1st draft SRA 10/2010
2nd draft SRA 10/2011
3rd draft SRA 08/2012
4th draft SRA 03/2013
5th draft SRA 06/2014
6th draft SRA

2nd MELODI Workshop Paris 10/2010
3rd MELODI Workshop Rome 10/2011
4th MELODI Workshop Helsinki 09/2012
5th MELODI Workshop Brussels 10/2013
6th MELODI Workshop Barcelona 10/2014
7th MELODI Workshop Munich 11/2015

MELODI Statement Oct 2011
MELODI Statement Nov 2010
MELODI Statement Nov 2013
MELODI Statement 2015

CONCERT Kick_Off meeting, Munich, 18 June 2015
Michaela Kreuzer 4
Task 2.1 Key activities

• The MELODI SRA is revised on a 5-year basis.

• During the SRA period, a SRA-statement is prepared annually and discussed by open consultation. This consultation will be finalized during the annual MELODI meeting. (⇒ M2)

• A long-term roadmap for research is developed by MELODI (⇒ M16)

• Annually, short-term research priorities are elaborated by MELODI.

• Providing input to Joint Programming (WP3)
Current status of work of the WG SRA

• Meeting of the MELODI WG SRA on 27th March 2015 in Munich

• Discussion on
  - Update of SRA
  - Development of the MELODI statement
  - Development of a roadmap

• Keeping in mind the timelines of MELODI and the CONCERT Project
Update of SRA

Structure of the SRA report

1. Executive Summary
2. Importance of low dose risk research
3. SRA (3 key research questions and priorities)
4. Synergistic topics of MELODI with other platforms
5. Education and Training
6. Infrastructures
7. Research priorities
8. Feasibility and impact assessment of research priorities
MELODI statement
First thoughts of the WG SRA

- Definition of one broad innovative topic, which allows the application of a multidisciplinary research group

- Definition of 3-5 short-term priorities for each key question (dose response cancer, non-cancer, individual sensitivity)

CONCERT:
- Provide MELODI statement end of July
- Joint priority setting meeting in September 2015
- Decision on budget balance between platforms and type of topics (broad or small) by Management Board
Difficult to develop a traditional roadmap in this field, because it is not possible to estimate what can be solved in which time line for the science in MELODI

Alternative:
- Definition of what is feasible for different dose ranges
- Feasibility and importance assessment for the three key questions

CONCERT:
- Joint roadmap and related budget allocation
- Year one: Propose a strategy for the development of a long-term roadmap